CA2616845A1 - Preparation en comprimes a liberation modifiee presentant des proprietes mecaniques ameliorees - Google Patents

Preparation en comprimes a liberation modifiee presentant des proprietes mecaniques ameliorees Download PDF

Info

Publication number
CA2616845A1
CA2616845A1 CA002616845A CA2616845A CA2616845A1 CA 2616845 A1 CA2616845 A1 CA 2616845A1 CA 002616845 A CA002616845 A CA 002616845A CA 2616845 A CA2616845 A CA 2616845A CA 2616845 A1 CA2616845 A1 CA 2616845A1
Authority
CA
Canada
Prior art keywords
hardness
eudragit
amount
tablet
dependent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002616845A
Other languages
English (en)
Inventor
Amir H. Shojaei
Melissa E. Culp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Supernus Pharmaceuticals Inc
Original Assignee
Supernus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supernus Pharmaceuticals Inc filed Critical Supernus Pharmaceuticals Inc
Publication of CA2616845A1 publication Critical patent/CA2616845A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002616845A 2005-07-28 2006-07-28 Preparation en comprimes a liberation modifiee presentant des proprietes mecaniques ameliorees Abandoned CA2616845A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70300005P 2005-07-28 2005-07-28
US60/703,000 2005-07-28
PCT/US2006/029427 WO2007016350A2 (fr) 2005-07-28 2006-07-28 Preparation en comprimes a liberation modifiee presentant des proprietes mecaniques ameliorees

Publications (1)

Publication Number Publication Date
CA2616845A1 true CA2616845A1 (fr) 2007-02-08

Family

ID=37692541

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002616845A Abandoned CA2616845A1 (fr) 2005-07-28 2006-07-28 Preparation en comprimes a liberation modifiee presentant des proprietes mecaniques ameliorees

Country Status (4)

Country Link
EP (1) EP1909767A2 (fr)
JP (1) JP2009502957A (fr)
CA (1) CA2616845A1 (fr)
WO (1) WO2007016350A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009087663A2 (fr) * 2007-11-30 2009-07-16 Sun Pharmaceutical Industries Ltd. Comprimé oral enrobé à libération contrôlée
CN102216458B (zh) 2008-11-13 2017-05-24 诺格拉制药有限公司 反义组合物及其制备和使用方法
AT10562U3 (de) * 2008-12-05 2010-01-15 Aop Orphan Pharmaceuticals Ag Neuartige zusammensetzung zur behandlung einer essenziellen thrombozytämie
LT2531181T (lt) * 2010-02-03 2019-07-10 Pharma Two B Ltd. Rasagilino uždelsto atpalaidavimo kompozicijos ir jų panaudojimas
CN102138906B (zh) * 2011-04-11 2012-09-05 合肥合源药业有限公司 一种盐酸可乐定缓释微丸制剂
EP4292587A1 (fr) 2022-06-15 2023-12-20 Sawai Pharmaceutical Co., Ltd. Préparation pharmaceutique contenant du chlorhydrate de guanfacine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2781152B1 (fr) * 1998-07-20 2001-07-06 Permatec Tech Ag Utilisation d'un polymere de type acrylique en tant qu'agent de desagregation
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6811794B2 (en) * 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles

Also Published As

Publication number Publication date
EP1909767A2 (fr) 2008-04-16
JP2009502957A (ja) 2009-01-29
WO2007016350A2 (fr) 2007-02-08
WO2007016350A3 (fr) 2007-05-31

Similar Documents

Publication Publication Date Title
AU2002249881B2 (en) Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US6811794B2 (en) Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
AU2002249881A1 (en) Sustained release pharmaceutical dosage forms with minimized PH dependent dissolution profiles
US6893661B1 (en) Controlled release formulations using intelligent polymers
EP2397122B1 (fr) Formulations de formes pharmaceutiques de néramexane
JP5726401B2 (ja) 単回投与形態の連日投与に適したグアンファシンの医薬品の剤形／組成物
US20060193912A1 (en) Controlled release O-desmethylvenlafaxine formulations
JPWO2006070781A1 (ja) 塩基性薬物又はその塩を含有するマトリックス型徐放性製剤およびその製造方法
RU2414241C2 (ru) Лекарственные композиции, содержащие гипромеллозные матрицы контролируемого высвобождения
CA2616845A1 (fr) Preparation en comprimes a liberation modifiee presentant des proprietes mecaniques ameliorees
US9616027B2 (en) Pramipexole sustained release tablet formulation and manufacturing method thereof and use thereof
WO2014151797A1 (fr) Formulations à libération prolongée résistant à la décharge de la dose d'alcool
JPWO2007080776A1 (ja) 徐放性製剤およびその製造方法
US20070104782A1 (en) Modified release tablet formulations with enhanced mechanical properties
WO2004037228A1 (fr) Compositions a liberation prolongee contenant de l'alfuzosine
EP2801350B1 (fr) Formulations pharmaceutiques de lacosamide
US7632521B2 (en) Controlled release potassium chloride tablets
CA3069948A1 (fr) Composition a dose fixe buccale solide comprenant de la metformine, du valsartan et de l'atorvastatine
TW201609196A (zh) 控制釋放製劑及其製備方法
EP3843702A1 (fr) Combinaison à dose fixe et à libération immédiate de mémantine et de donépézil
NZ760868B2 (en) A solid oral fixed dose composition comprising metformin, valsartan and atorvastatin

Legal Events

Date Code Title Description
FZDE Dead